Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.1    
    

 
 

TRIQUINT SEMICONDUCTOR, INC.
  
  1996 STOCK INCENTIVE PROGRAM
  
  (AS AMENDED EFFECTIVE MAY 2004)    
    

        1.
Purposes of the Program.    The purposes of this Stock Incentive Program are to attract and retain the best available
personnel for positions of substantial responsibility, to provide additional incentive to the Employees, Consultants and certain Outside Directors of the Company and to promote the success of the
Company's business. 

        Options
granted hereunder may be either Incentive Stock Options or Nonstatutory Stock Options, at the discretion of the Administrator and as reflected in the terms of the Option
Agreement. The Program also provides for automatic grants of Nonstatutory Stock Options to Outside Directors who are neither representatives nor employees or stockholders owning more than one percent
(1%) of the outstanding shares of the Company. 

        2.  Definitions.    As used herein, the following definitions shall apply: 

        (a)   "Administrator" shall mean the Board or any of its Committees as shall be administering the Program, in accordance with
Section 4 of the Program. 

        (b)   "Applicable Laws" means the requirements relating to the administration of stock option plans under U.S. state corporate
laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or
jurisdiction where Options or Stock Purchase Rights are, or will be, granted under the Program. 

        (c)   "Board" shall mean the Board of Directors of the Company. 

        (d)   "Code" shall mean the Internal Revenue Code of 1986, as amended. 

        (e)   "Common Stock" shall mean the Common Stock of the Company. 

        (f)    "Company" shall mean TriQuint Semiconductor, Inc., a Delaware corporation. 

        (g)   "Committee" shall mean a Committee appointed by the Board of Directors in accordance with Section 4 of the
Program. 

        (h)   "Consultant" shall mean any person who is engaged by the Company or any Parent or Subsidiary to render consulting
services and is compensated for such consulting services; provided that the term Consultant shall not include directors who are not compensated for their services; or are paid only a director's fee by
the Company. 

        (i)    "Continuous Status as an Employee, Consultant or Outside Director" shall mean the absence of any interruption or
termination of service as an Employee, Consultant or Outside Director. Continuous Status as an Employee, Consultant or Outside Director shall not be considered interrupted in the case of sick leave,
military leave, or any other leave of absence approved by the Administrator. 

        (j)    "Director" shall mean a member of the Board. 

        (k)   "Employee" shall mean any person, including officers and directors, employed by the Company or any Parent or Subsidiary
of the Company. The payment of a director's fee by the Company shall not be sufficient to constitute "employment" by the Company. 

        (l)    "Exchange Act" shall mean the Securities Exchange Act of 1934, as amended. 

        (m)  "Incentive Stock Option" shall mean an Option intended to qualify as an incentive stock option within the meaning of
Section 422 of the Code and the regulations promulgated thereunder. 

 

        (n)   "Nonstatutory Stock Option" shall mean an Option not intended to qualify as an Incentive Stock Option. 

        (o)   "Officer" shall mean a person who is an officer of the Company within the meaning of Section 16 of the Exchange
Act and the rules and regulations promulgated thereunder. 

        (p)   "Option" shall mean a stock option granted pursuant to the Program. 

        (q)   "Option Agreement" means a written or electronic agreement between the Company and an Optionee evidencing the terms and
conditions of an individual Option grant. The Option Agreement is subject to the terms and conditions of the Plan. 

        (r)   "Optioned Stock" shall mean the Common Stock subject to an Option. 

        (s)   "Optionee" shall mean an Employee, Consultant or Outside Director who holds an outstanding Option. 

        (t)    "Outside Director" shall mean a member of the Board of Directors of the Company who is not an Employee. 

        (u)   "Parent" shall mean a "parent corporation", whether now or hereafter existing, as defined in Section 424(e) of the
Code. 

        (v)   "Program" shall mean this 1996 Stock Incentive Program. 

        (w)  "Retirement" shall mean the termination of an Optionee's Continuous Status as an Employee, Consultant or Outside Director
when any of the following are true: (i) the Optionee is at least fifty-five (55) years old and he or she has completed at least seven (7) years of service as an
Employee, Consultant, or, if applicable, Outside Director, (ii) the Optionee is at least sixty-three (63) years old, or (iii) the Optionee's age when added to the number of years
of service as an Employee, Consultant or, if applicable, Outside Director equals or exceeds seventy (70). 

        (x)   "Rule 16b-3" shall mean Rule 16b-3 of the Exchange Act or any successor to
Rule 16b-3, as in effect when discretion is being exercised with respect to the Program. 

        (y)   "Share" shall mean a share of the Common Stock, as adjusted in accordance with Section 10 of the Program. 

        (z)   "Subsidiary" shall mean a "subsidiary corporation", whether now or hereafter existing, as defined in
Section 424(f) of the Code. 

        3.  Stock Subject to the Program.    Subject to the provisions of Section 10 of the Program, the maximum aggregate
number
of shares under the Program is 36,050,000 shares of Common Stock. The Shares may be authorized, but unissued, or reacquired Common Stock. 

        If
an Option should expire or become unexercisable for any reason without having been exercised in full, the unpurchased Shares which were subject thereto shall, unless the Program shall
have been terminated, become available for future grant under the Program. Notwithstanding the above, however, if Shares are issued upon exercise of an Option and later repurchased by the Company,
such Shares shall not become available for future grant or sale under the Program. 

        4.
Administration of the Program. 

        (a)   Procedure. 

        (i)    Multiple Administrative Bodies.    The Program may be administered by different Committees with respect to
different groups of Service Providers. 

        (ii)   Section 162(m).    To the extent that the Administrator determines it to be desirable to qualify
Options granted hereunder as "performance-based compensation" within the 

2

 

meaning
of Section 162(m) of the Code, the Program shall be administered by a Committee of two or more "outside directors" within the meaning of Section 162(m) of the Code. 

        (iii)  Rule 16b-3.    To the extent desirable to qualify transactions hereunder as exempt under
Rule 16b-3, the transactions contemplated hereunder shall be structured to satisfy the requirements for exemption under Rule 16b-3. 

        (iv)  Other Administration.    Other than as provided above, the Program shall be administered by (A) the
Board or (B) a Committee, which committee shall be constituted to satisfy Applicable Laws. 

        (b)   Power of the Administrator.    Subject to the provisions of the Program, the Administrator shall have the
authority, in its discretion: (i) to grant Incentive Stock Options or Nonstatutory Stock Options; (ii) to approve forms of agreement for use under the Program; (iii) to determine,
upon review of relevant information and in accordance with Section 7 of the Program, the fair market value of the Common Stock; (iv) to determine the exercise price per share of Options
to be granted, which exercise price shall be determined in accordance with Section 7 of the Program; (v) to determine the Employees or Consultants to whom, and the time or times at
which, Options shall be granted and the number of shares to be represented by each Option (except with respect to automatic Option grants made to certain Outside Directors); (vi) to interpret
the Program; (vii) to prescribe, amend and rescind rules and regulations relating to the Program; (viii) to determine the terms and provisions of each Option granted (which need not be
identical) and, with the consent of the holder thereof, modify or amend each Option; (ix) to authorize any person to execute on behalf of the Company any instrument required to effectuate the
grant of an Option previously granted by the Administrator; (x) to allow Optionees to satisfy withholding tax obligations by electing to have the Company withhold from the Shares to be issued
upon exercise of an Option that number of Shares having a Fair Market Value equal to the minimum amount required to be withheld; (xi) to reduce the exercise price of any Option to the then
current Fair Market Value if the Fair Market Value of the Common Stock covered by such Option shall have declined since the date the Option was granted;  provided, however, that the Administrator must seek the prior consent of the Board of Directors and
stockholders of the Company to effect such action; and (xii) to make all other determinations deemed necessary or advisable for the administration of the Program. However, with respect to
Options granted to certain Outside Directors pursuant to Section 8(b)(ii) hereof, the Administrator shall exercise no discretion and such awards shall be administered solely according to
their terms. 

        (c)   Effect of Administrator's Decision.    All decisions, determinations and interpretations of the Administrator
shall be final and binding on all Optionees and any other holders of any Options granted under the Program. 

        5.
Eligibility. 

        (a)   Options
may be granted to Employees and Consultants; Options may also be granted to Outside Directors who are neither employees nor representatives of stockholders
owning more than one percent (1%) of the outstanding shares of the Company. However, (i) Incentive Stock Options may be granted only to Employees, and (ii) Options may only be granted to
Outside Directors who are neither employees nor representatives of stockholders owning more than one percent (1%) of the outstanding shares of the Company in accordance with the provisions of
Section 8(b)(ii) hereof. An Employee, Consultant or Outside Director who has been granted an Option may, if he is otherwise eligible, be granted an additional Option or Options. 

        (b)   To
the extent that the aggregate fair market value of Shares subject to an Optionee's incentive stock options granted by the Company, any Parent or Subsidiary, which
become exercisable for the first time during any calendar year (under all plans or programs of the 

3

 

Company
or any Parent or Subsidiary) exceeds $100,000, such excess Options shall be treated as Nonstatutory Stock Options. For purposes of this Section 5(b), incentive stock options shall be
taken into account in the order in which they were granted, and the fair market value of the Shares shall be determined as of the time of grant. 

        (c)   Neither
the Program nor any Option shall confer upon any Optionee any right with respect to continuation of employment or consulting relationship with the Company, nor
shall it interfere in any way with the Optionee's right or the Company's right to terminate such employment or consulting relationship at any time with or without cause. 

        (d)   The
following limitations shall apply to grants of Options under the Program (defined below): 

        (i)    The
President of the Company shall not be granted, in any fiscal year of the Company, options to purchase more than 1,500,000 Shares, and no other Employee shall be
granted, in any fiscal year of the Company, Options to purchase more than 750,000 Shares. 

        (ii)   The
foregoing limitations shall be adjusted proportionately in connection with any change in the Company's capitalization as described in Section 10. 

        (iii)  If
an Option is canceled in the same fiscal year of the Company in which it was granted (other than in connection with a transaction described in Section 10),
the canceled Option will be counted against the limit set forth in Section (i) above. For this purpose, if the exercise price of an Option is reduced, the transaction will be treated as a
cancellation of the Option and the grant of a new Option. 

        (iv)  The
foregoing limitations set forth in this Section 5(d) are intended to satisfy the requirements applicable to Options intended to qualify as "performance-based
compensation" (within the meaning of Section 162(m) of the Code). In the event the Administrator determines that such limitations are not required to qualify Options as performance-based
compensation, the Administrator may modify or eliminate such limitations. 

        6.  Term of Program.    The Program shall become effective upon the earlier to occur of its adoption by the Board of
Directors or
its approval by vote of the stockholders of the Company as described in Section 16 of the Program. It shall continue in effect for a term of ten (10) years unless sooner terminated under
Section 12 of the Program. 

        7.
Exercise Price and Consideration of Shares. 

        (a)   The
per Share exercise price for the Shares to be issued pursuant to exercise of an Option shall be such price as is determined by the Administrator, but in no event
shall it be less than 100% of the fair market value per Share on the date of grant. In the case of an Incentive Stock Option granted to an Employee who, at the time of grant of such Incentive Stock
Option owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price shall be no less than
110% of the fair market value per Share on the date of grant. 

        (b)   The
fair market value shall be determined by the Administrator; provided, however, in the event that the Common Stock is listed on any established stock exchange or a
national market system, including without limitation the Nasdaq National Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market, its fair market value shall be the closing sales price for
such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system for the trading day that is the time of determination (or if such time of determination does not occur
on a trading day, the last trading day prior to the time of determination), as reported in THE WALL STREET JOURNAL or such other source as the Administrator deems reliable; or in the event that the
Common Stock is regularly quoted by a recognized securities dealer but selling prices are 

4

 

not
reported, the fair market value of a Share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the last market trading day prior to the day of
determination, as reported in THE WALL STREET JOURNAL or such other source as the Administrator deems reliable. 

        (c)   The
consideration to be paid for the Shares to be issued upon exercise of an Option, including the method of payment, shall be determined by the Board and may consist
entirely of: 

        (i)    cash,

        (ii)   check,

        (iii)  other
Shares of Common Stock which (i) either have been vested and owned by the Optionee for more than six (6) months on the date of surrender or were
not acquired, directly or indirectly, from the Company, and (ii) have a fair market value on the date of surrender equal to the aggregate exercise price of the Shares as to which said option
shall be exercised, 

        (iv)  delivery
of a properly executed exercise notice together with such other documentation as the Administrator and the broker, if applicable, shall require to effect an
exercise of the Option and delivery to the Company of the sale proceeds required to pay the exercise price, or 

        (v)   any
combination of such methods of payment. 

        In
making its determination as to the type of consideration to accept, the Administrator shall consider if acceptance of such consideration may be reasonably expected to benefit the
Company. 

        However,
with respect to Options granted to certain Outside Directors pursuant to Section 8(b)(ii) hereof, the consideration to be paid for the Shares to be issued upon
exercise of an Option, including the method of payment, shall consist entirely of the types of consideration listed in Section 7(c)(i), (ii), (iii), (iv) and (v) above. 

        8.
Options. 

        (a)   Term of Option.    The term of each Option shall be ten (10) years from the date of grant thereof or
such shorter term as may be provided by the Administrator. The term of each Option that is not an Incentive Stock Option shall be ten (10) years and one (1) day from the date of grant
thereof or such shorter term as may be provided by the Administrator. However, in the case of an Option granted to an Optionee who, at the time the Option is granted, owns stock representing more than
ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, (a) if the
Option is an Incentive Stock Option, the term of the Option shall be five (5) years from the date of grant thereof or such shorter time as may be provided by the Administrator, or (b) if
the Option is not an Incentive Stock Option, the term of the Option shall be five (5) years and one (1) day from the date of grant thereof or such shorter term as may be provided by the
Administrator. However, with respect to Options granted to certain Outside Directors pursuant to Section 8(b)(ii) hereof the term shall be as stated in such Section. 

        (b)   Exercise of Option. 

        (i)    Procedure for Exercise; Rights as a Stockholder.    Any Option granted hereunder, except for Options granted to
certain Outside Directors in accordance with Section 8(b)(ii) below, shall be exercisable at such times and under such conditions as determined by the Administrator, including
performance criteria with respect to the Company and/or the Optionee, and shall be permissible under the terms of the Program. 

        An
Option may not be exercised for a fraction of a Share. 

5

 

        An
Option shall be deemed to be exercised when written notice of such exercise has been given to the Company either by a signed writing or electronic transmission in accordance with the
terms of the Option by the person entitled to exercise the Option and full payment for the Shares with respect to which the Option is exercised has been received by the Company. Full payment may, as
authorized by the Administrator, consist of any consideration and method of payment allowable under Section 7(c) of the Program. Until the issuance (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company) of the stock certificate evidencing such Shares, which issuance shall be made as soon as is practicable, no right to vote or
receive dividends or any other rights as a stockholder shall exist with respect to the Optioned Stock, notwithstanding the exercise of the Option. The Company shall issue (or cause to be issued) such
stock certificate promptly upon exercise of the Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date the stock certificate is issued, except
as provided in Section 10 of the Program. 

        Exercise
of an Option in any manner shall result in a decrease in the number of Shares which thereafter may be available, both for purposes of the Program and for sale under the Option,
by the number of Shares as to which the Option is exercised. 

        (ii)   Automatic Option Grants to Certain Outside Directors.    The provisions set forth in this
Section 8(b)(ii) shall not be amended more than once every six months, other than to comport with
changes in the Code, the Employee Retirement Income Security Act of 1974 as amended, or the rules or regulations promulgated thereunder. All grants of Options to Outside Directors under this Program
shall be automatic and non-discretionary and shall be made strictly in accordance with the following provisions: 

        (A)  No
person shall have any discretion to select which Outside Directors shall be granted Options or to determine the number of shares to be covered by Options granted to
Outside Directors; provided, however, that nothing in this Program shall be construed to prevent an Outside Director from declining to receive an Option under this Program. 

        (B)  On
the date of each annual meeting of the Company's stockholders, each person who is then an Outside Director (including any person who first becomes an Outside Director
as of such date) and who is not a representative of stockholders owning more than one percent (1%) of the outstanding shares of the Company shall automatically receive an Option to purchase 17,500
Shares (the "Complete Annual Grant"). 

        (C)  Each
Outside Director who is not a representative of stockholders owning more than one percent (1%) of the outstanding shares of the Company and who first becomes an
Outside Director as of a date other than the date of an annual meeting of the Company's stockholders shall automatically receive, upon such date, an Option (the "Partial Annual Grant" and collectively
with the Complete Annual Grant, the "Annual Grants") to purchase that number of Shares obtained by multiplying 17,500 by a fraction, the numerator of which is the difference obtained by subtracting
from 12 the number of whole calendar months that have elapsed since the date of the previous annual meeting of the Company's stockholders and the denominator of which is 12. 

        (D)  Upon
such person's election or appointment as an Outside Director, each person who becomes an Outside Director shall automatically receive an Option (the Initial Grant")
to purchase 33,000 Shares; provided, however that an Inside Director who ceases to be an Inside Director but who remains a Director shall not receive such automatic grant. 

6

 

        (E)  The
terms of an Option granted pursuant to this Section 8(b)(ii) shall be as follows: 

        (1)   the
term of the Annual Grants shall be five (5) years and the term of the Initial Grants shall be 10 years; 

        (2)   except
as provided in Sections 8(b)(iii), 8(b)(iv), 8(b)(v), and 8(b)(vi) of this Program, the Option shall be exercisable only while the Outside Director remains
a director; 

        (3)   the
exercise price per share of Common Stock shall be 100% of the fair market value on the date of grant of the Option; 

        (4)   the
Annual Grants shall become exercisable in installments cumulatively with respect to twenty-five percent (25%) of the Optioned Stock six months after the
date of grant and as to an additional twelve and one-half percent (12.5%) of the Optioned Stock each calendar quarter thereafter, so that one hundred percent (100%) of the Optioned Stock
shall be exercisable two years after the date of grant, subject to the Outside Director remaining a Director through each applicable vesting date; provided, however, that in no event shall any Option
be exercisable prior to obtaining stockholder approval of the Program. 

        (5)   the
Initial Grants shall become exercisable in installments cumulatively with respect to twenty-eight percent (28%) of the Optioned Stock one year after the date of
grant and as to an additional two percent (2%) of the Optioned Stock each calendar month thereafter, so that one hundred percent (100%) of the Optioned Stock shall be exercisable four years after the
date of grant, subject to the Outside Director remaining a Director through each applicable vesting date. 

        (iii)  Termination of Status as an Employee, Consultant or Outside Director.    Unless otherwise provided by the
Administrator, in the event of termination of an Optionee's Continuous Status as an Employee, Consultant or Outside Director, such Optionee may, but only within three (3) months (or, for
Options not granted pursuant to Section 8(b)(ii) hereof, for such other period of time, not exceeding three (3) months in the case of an Incentive Stock Option or six
(6) months in the case of a Nonstatutory Stock Option, as is determined by the Administrator, with such determination in the case of an Incentive Stock Option being made at the time of grant of
the Option) after the date of such termination (but in no event later than the date of expiration of the term of such Option as set forth in the Option Agreement), exercise his or her Option to the
extent that the Optionee was entitled to exercise it as of the date of such termination. To the extent that the Optionee was not entitled to exercise the Option at the date of such termination, or if
the Optionee does not exercise such Option (which the Optionee was entitled to exercise) within the time specified herein, the Option shall terminate. 

        (iv)  Disability of Optionee.    Notwithstanding the provisions of Section 8(b)(iii) above, unless
otherwise provided by the Administrator, in the event of termination of an Optionee's Continuous Status as an Employee, Consultant or Outside Director as a result of his or her total and permanent
disability (as defined in Section 22(e)(3) of the Code), the Optionee may, until the date of expiration of the term of such Option as set forth in the Option Agreement (or such shorter period
of time as provided by the Administrator), exercise his or her Option to the extent the Optionee was entitled to exercise it at the date of such termination. To the extent that the Optionee was not
entitled to exercise the Option at the date of termination, or if the Optionee does not exercise such Option (which the Optionee was entitled to exercise) within the time specified herein, the Option
shall terminate. 

7

 

        (v)   Death of Optionee.    In the event of the death of an Optionee: 

        (A)  during
the term of the Option, where the Optionee is at the time of his or her death an Employee, Consultant or Outside Director of the Company and where such Optionee
shall have been in Continuous Status as an Employee, Consultant or Outside Director since the date of grant of the Option, the Option may be exercised, at any time within one (1) year following
the date of death, by the Optionee's estate or by a person who acquired the right to exercise the Option by bequest or inheritance, to the extent that he and she was entitled to exercise it at the
date of death; or 

        (B)  within
three (3) months after the termination of Continuous Status as an Employee, Consultant or Outside Director for any reason other than for cause or a
voluntary termination initiated by the Optionee, the Option may be exercised, at any time within one (1) year following the date of death, by the Optionee's estate or by a person who acquired
the right to exercise the Option by bequest or inheritance, but only to the extent of the right to exercise that had accrued at the date of termination. 

        (vi)  Retirement.    Notwithstanding the provisions of Section 8(b)(ii) above, unless otherwise
provided by the Administrator, in the event of termination of an Optionee's Continuous Status as an Employee, Consultant or Outside Director as a result of his or her Retirement, the Optionee may,
until the date of expiration of the term of such Option as set forth in the Option Agreement (or such shorter period of time as provided by the Administrator), exercise his or her Option to the extent
the Optionee was entitled to exercise it at the date of such termination. To the extent that the Optionee was not entitled to exercise the Option at the date of termination, or if the Optionee does
not exercise such Option (which the Optionee was entitled to exercise) within the time specified by the Administrator, the Option shall terminate. 

        9.
Non-Transferability of Options.    During the lifetime of the Optionee, an Option shall be exercisable only by
the Optionee or the Optionee's guardian, legal representative or permitted transferees. Except as specified below, no Option may be sold, transferred, pledged, assigned, or otherwise alienated or
hypothecated, other than by will or by the laws of descent and distribution. At
the sole discretion of the Administrator, and subject to such terms and conditions as the Administrator deems advisable, the Administrator may allow (a) the transfer of a Nonstatutory Stock
Option to an Optionee's spouse, former spouse or dependent pursuant to a court-approved domestic relations order which relates to the provision of child support, alimony payments or marital property
rights and (b) the transfer of a Nonstatutory Stock Option by bona fide gift and not for any consideration, to (i) a member or members of the Optionee's Immediate Family, (ii) a
trust established for the exclusive benefit of the Optionee and/or member(s) of the Optionee's Immediate Family, (iii) a partnership, limited liability company of other entity whose only
partners or members are the Optionee and/or member(s) of the Optionee's Immediate Family, or (iv) a foundation in which the Optionee and/or member(s) of the Optionee's Immediate Family control
the management of the foundation's assets. "Immediate Family" as used herein means the spouse, lineal descendants, father, mother, brothers and sisters of the Optionee. In such case, the transferee
shall receive and hold the Option subject to the provisions of this Section 9, and there shall be no further assignation or transfer of the Option. The terms of Options granted hereunder shall
be binding upon the transferees, purchasers, executors, administrators, heirs, successors and assigns of the Optionee. 

        10.
Adjustments Upon Changes In Capitalization or Merger.    Subject to any required action by the stockholders of the Company,
the number of shares of Common Stock covered by each outstanding Option, and the number of shares of Common Stock which have been authorized for issuance under the Program but as to which no Options
have yet been granted or which have been returned to the Program upon cancellation or expiration of an Option, as well as the price per share of Common Stock 

8

 

covered
by each such outstanding Option, shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock
split, stock dividend, combination or reclassification of the Common Stock, or any other increase or decrease in the number of issued shares of Common Stock effected without receipt of consideration
by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been "effected without receipt of consideration." Such adjustment shall be
made by the Administrator, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares of stock of any class,
or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to
an Option. 

        In
the event of the proposed dissolution or liquidation of the Company, the Board shall notify the holder of an Option at least fifteen (15) days prior to such proposed action. To
the extent it has not been previously exercised, the Option will terminate immediately prior to the consummation of such proposed action. 

        In
the event of a merger of the Company with or into another corporation, or the sale of all or substantially all of the Company's assets, the Option shall be assumed or an equivalent
option shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation, unless the Administrator determines, in the exercise of its sole discretion and in
lieu of such assumption or substitution, that the Optionee shall have the right to exercise the Option as to all of the Optioned
Stock, including as to Shares as to which the Option would not otherwise be exercisable. If the Administrator makes an Option fully exercisable in lieu of assumption or substitution in the event of a
merger or sale of assets, the Administrator shall notify the Optionee that the Option shall be fully exercisable for a period of thirty (30) days from the date of such notice, and the Option
will terminate upon the expiration of such period. Provided, however, that notwithstanding any other provision of this Program, Options granted pursuant to Section 8(b)(ii) hereof shall,
in the event of a merger of the Company with or into another corporation or the sale of all or substantially all of the Company's assets, be assumed or an equivalent option shall be substituted by
such successor corporation or a parent or subsidiary of such successor corporation; provided, further, however, that in the event the successor corporation or a parent or subsidiary of such successor
corporation refuses to so assume or substitute such options, such options shall become fully vested and exercisable including as to Shares as to which such Options would not otherwise be exercisable.
For the purposes of this paragraph, the Option shall be considered assumed if, following the merger or asset sale, the option confers the right to purchase, for each Share subject to the Option
immediately prior to the merger or asset sale, the consideration (whether stock, cash, or other securities or property) received in the merger or asset sale by holders of Common Stock for each Share
held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares);
provided, however, that if such consideration received in the merger or sale of assets was not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent
of the successor corporation, provide for the consideration to be received upon the exercise of the Option, for each Share subject to the Option, to be solely common stock of the successor corporation
or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the merger or sale of assets. 

        11.  Time of Granting Options.    The date of grant of an Option shall be the date on which the Administrator makes the
determination granting such Option, except with respect to the date of grant of Options to certain Outside Directors, which is set by the terms of the Program. Notice of the determination shall be
given to each Employee or Consultant to whom an Option is granted within a reasonable time after the date of such grant. 

9

 

        12.  Amendment and Termination of the Program. 

        (a)   Amendment and Termination.    The Board may at any time amend, alter, suspend or terminate the Program. 

        (b)   Stockholder Approval.    The Company shall obtain stockholder approval of any Program amendment to the extent
necessary and desirable to comply with Section 422 of the Code (or any successor rule or statute or other applicable law, rule or regulation, including the requirements of any exchange or
quotation system on which the Common Stock is listed or quoted). Such stockholder approval, if required, shall be obtained in such a manner and to such a degree as is required by the applicable law,
rule or regulation. In addition, should the Administrator determine that it is appropriate to reduce the
exercise price of any Option pursuant to Section 4(b)(xi) of the Program, the Administrator shall seek the prior consent of the stockholders to effect such action. 

        (c)   Effect of Amendment or Termination.    No amendment, alteration, suspension or termination of the Program shall
impair the rights of any Optionee, unless mutually agreed otherwise between the Optionee and the Administrator, which agreement must be in writing and signed by the Optionee and the Company. 

        13.
Conditions Upon Issuance of Shares.    Shares shall not be issued pursuant to the exercise of an Option unless the exercise
of such Option and the issuance and delivery of such Shares pursuant thereto shall comply with all relevant provisions of law, including, without limitation, the Securities Act of 1933, as amended
(the "Securities Act"), the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the Shares may then be listed, and shall be further
subject to the approval of counsel for the Company with respect to such compliance. 

        As
a condition to the exercise of an Option, the Company may require the person exercising such Option or making such purchase to represent and warrant at the time of any such exercise
that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is
required by any of the aforementioned relevant provisions of law. 

        14.  Reservation of Shares.    The Company, during the term of this Program, will at all times reserve and keep
available such
number of Shares as shall be sufficient to satisfy the requirements of the Program. 

        15.
Inability to Obtain Authority.    Inability of the Company to obtain authority from any regulatory body having jurisdiction,
which authority is deemed by the Company's counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to
issue or sell such Shares as to which such requisite authority shall not have been obtained. 

        16.  Stockholder Approval.    Continuance of the Program shall be subject to approval by the stockholders of the
Company within
twelve months before or after the date the Program is adopted. Such stockholder approval shall be obtained in the manner and to the degree required under applicable federal and state law. 

10

QuickLinks

Exhibit 4.1

TRIQUINT SEMICONDUCTOR, INC. 1996 STOCK INCENTIVE PROGRAM (AS AMENDED EFFECTIVE MAY 2004)QuickLinks
 -- Click here to rapidly navigate through this document

  

CONFIDENTIAL TREATMENT REQUEST 

	*
	Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

EXHIBIT 10.1  

 
  PURCHASE AND SALE AGREEMENT    
    

        THIS PURCHASE AND SALE AGREEMENT (this "Agreement"), is made and entered into as of February 11, 2004,
between Pfizer Inc., a Delaware corporation with a place of business at 235 East 42nd Street, New York, New York 10017 ("Pfizer"), and
SuperGen, Inc., a Delaware corporation with a place of business at 4140 Dublin Boulevard, Suite 200, Dublin, California 94568 ("SuperGen").
Pfizer and SuperGen are collectively referred to as the "Parties" and each, individually, a "Party". 

RECITALS  

        WHEREAS, SuperGen previously entered into the following agreements with the Warner-Lambert Company (now
Warner-Lambert Company LLC) ("WLC") related to the manufacture, packaging, marketing, and sale of Pentostatin: a Purchase and Sale Agreement dated
September 30, 1996 (the "Purchase Agreement"), and a Supply Agreement dated October 13, 1997 (the "Supply
Agreement"); and 

        WHEREAS, the WLC previously entered into that certain Distribution Agreement dated June 1, 1992, as amended, with the American
Cyanamid Corporation (the "Distribution Agreement"); and 

        WHEREAS, Wyeth (together with its predecessors in interest with respect to the Distribution Agreement,
"Wyeth") subsequently acquired the American Cyanamid Corporation, and is now party to the Distribution Agreement; and 

        WHEREAS, Pfizer subsequently acquired WLC, and WLC is now a wholly-owned subsidiary of Pfizer; and 

        WHEREAS, the Parties desire (i) to terminate the Supply Agreement, (ii) that Pfizer cause the Asset Selling Corporations to
transfer the Assets (hereinafter defined) to SuperGen or its designated Affiliate, and (iii) that SuperGen take assignment of the Distribution Agreement from WLC, in each case upon the terms
and conditions as set forth herein below. 

        NOW, THEREFORE, in consideration of the covenants, promises, representations and warranties set forth herein, and for other good and
valuable consideration (the receipt and sufficiency of which are hereby acknowledged by the Parties), intending to be legally bound hereby, the Parties agree as follows: 

ARTICLE 1

DEFINITIONS  

        The following capitalized terms shall have the meanings set forth below: 

         1.1  "Affiliate" means any entity that controls, is controlled by or is under common control with a Party. For purposes of
this definition, "control" shall mean direct or indirect ownership of more than fifty percent (50%) of the shares of the respective entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing authority). 

         1.2  "Assets" means the Marketing Approvals and the Trademarks. 

         1.3  "Asset Selling Corporations" shall mean the entities listed on  Schedule 1.3. 

1

 

         1.4  "Books and Records" means the books and records of Pfizer related to (i) the Marketing Approvals, and
(ii) the Distribution Agreement and Pfizer's performance thereunder prior to the Closing Date, including Pfizer's Product sales records and relevant correspondence with Wyeth. 

         1.5  "Business Day" means shall mean any day other than a Saturday, a Sunday or a day on which banks in New York, New York,
United States of America are authorized or obligated by law or executive order to close. 

         1.6  "Closing" shall mean the closing of the transactions contemplated by this Agreement pursuant to the terms of this
Agreement. 

         1.7  "Closing Deadline" means March 31, 2004. 

         1.8  "Drug Master Files" means all drug master files that are referred to or referenced in New Drug Application
No. 20122-001, and owned or controlled by or in the possession of Pfizer. 

         1.9  "EMEA" means The European Agency for the Evaluation of Medicinal Products. 

       1.10  "Knowledge" means the actual knowledge of the individuals listed on  Schedule 1.10. 

       1.11  "Labeling" shall mean any and all printed labels, labeling and package inserts for the Product for countries or
jurisdictions outside of the Prior Territory. 

       1.12  "Liabilities" shall mean any debts, liabilities or obligations, whether accrued or fixed, known or unknown, absolute or
contingent, matured or unmatured or determined or determinable. 

       1.13  "Marketing Approvals" means any and all active or inactive (i) approvals, licenses, registrations and
authorizations, of all governmental agencies in a jurisdiction for the development, manufacture, use or sale of the Product in the applicable jurisdiction, including any pricing or reimbursement
approval with respect to the sale of the Product in the applicable jurisdiction; and (ii) applications for any of the foregoing; in each case in countries or jurisdictions outside the Prior
Territory. Schedule 1.13 attached hereto sets forth a complete list of all Marketing Approvals and the status thereof as of the Closing Date,
including the date of any required renewals after the Closing Date. 

       1.14  "Patents" shall mean any of the following, as of the Closing Date: (i) any issued and unexpired patent, including
without limitation inventor's certificates, utility model, substitutions, extensions, confirmations, reissues, re-examination, renewal or any like governmental grant for protection of
inventions; and (ii) any pending application for any of the foregoing, including without limitation any continuation, divisional, substitution, additions,
continuations-in-part, provisional and converted provisional applications. 

       1.15  "Pentostatin" means the pharmaceutical compound (R) -3 -
(deoxy-ß-D-erythropentofuranosyl) -3, 6, 7, 8-tetrahydroimidazo [4, 5-d] [1, 3]
diazepin-8-01. 

       1.16  "Prior Territory" means Canada, Mexico and the United States of America, along with all its territories and possessions,
the Commonwealth of Puerto Rico and the District of Columbia. 

       1.17  "Product" means any pharmaceutical preparation for human use using Pentostatin as the sole active ingredient. 

       1.18  "Product Claim" shall mean a claim from a third party for money or other compensation (beyond reimbursement for the cost
of the Product) in respect of potential or actual injury or harm allegedly due and owing as a result of the use, application or defect of the Product or Labeling of the Product, in each case solely
with respect to Product sold or offered for sale outside of the Prior Territory, irrespective of the legal theory of liability. 

2

 

       1.19  "Regulatory Authority" shall mean any federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the development, manufacture or commercialization (including review and approval of Marketing Approvals) with respect to the Product
outside of the Prior Territory. 

       1.20  "Subsequent Acquired Know-How" means Acquired Know-How (as that term is defined in the Purchase
Agreement) to the extent such Acquired Know-How was not conveyed to SuperGen pursuant to the Purchase Agreement. 

       1.21  "Subsequent Licensed Know-How" means Licensed Know-How (as that term is defined in the Purchase
Agreement) owned or licensed by Pfizer or its Affiliates as of the Closing Date to the extent such Licensed Know-How has not been delivered to SuperGen pursuant to the Purchase Agreement. 

       1.22  "Taxes" means all taxes, charges, duties, fees, levies or other assessments, including but not limited to, income,
excise, property, sales, value added, profits, license, withholding (with respect to compensation or otherwise), payroll, employment, net worth, capital gains, transfer, stamp, social security,
environmental, occupation and franchise taxes, imposed by any governmental authority, and including any interest, penalties and additions attributable thereto. 

       1.23  "Tax Return" means any return, report, declaration, information return, statement or other document filed or required to
be filed with any governmental authority, in connection with the determination, assessment or collection of any Tax or the administration of any laws relating to any Tax. 

       1.24  "Trademarks" means the trademarks listed in Schedule 1.24
attached hereto. 

ARTICLE 2

DISPOSITION OF ASSETS, AGREEMENTS AND PURCHASE PRICE  

        2.1    Conveyance.    

        (a)   Effective
as of the Closing Date and subject to the terms and conditions of this Agreement, Pfizer hereby sells, conveys, transfers, assigns, delivers and shall cause
the Asset Selling Corporations to sell, convey, transfer, assign and deliver to SuperGen or its designated Affiliate(s) all rights, title and interest in and to the Assets, free and clear of all liens
or encumbrances of any kind. 

        (b)   Excluded Assets.    Notwithstanding any other provision in this Agreement, Pfizer or any of its Affiliates
shall retain the following (the "Excluded Assets"): 

          (i)  the
"Pfizer," "Warner-Lambert," "Parke-Davis," "Searle," and "Pharmacia" trademarks, trade names and logos; 

         (ii)  the
corporate books and records of the Asset Selling Corporations and the general account and books of original entry that comprise the Asset Selling Corporations'
permanent accounting or tax records; and 

        (iii)  all
assets not expressly included in the Assets. 

        (c)   Assumption of Certain Liabilities.    Upon the terms and subject to the conditions of this Agreement, SuperGen
agrees, effective at the Closing, except as set forth in Section 2.1(d), to assume all the following Liabilities of the Asset Selling Corporations (collectively, the
"Assumed Liabilities"): 

          (i)  all
Liabilities arising out of or relating to any Product Claim arising from events or activities after the Closing; 

         (ii)  all
Liabilities for lawsuits commenced after the Closing to the extent relating to the Trademarks; 

3

 

        (iii)  all
Liabilities under any contracts, agreements, licenses or commitments that are assigned to SuperGen at or after the Closing arising from events or activities after
the Closing; and 

        (iv)  all
other Liabilities relating solely to the Product to the extent arising from events or activities after the Closing. 

        (d)   Retained Liabilities.    Notwithstanding any provision in this Agreement to the contrary, Pfizer shall, or
shall cause one of the Asset Selling Corporations to, retain and be responsible for the following (the "Retained Liabilities"): 

          (i)  all
Liabilities arising out of or relating to any Product Claim arising from events or activities prior to the Closing; 

         (ii)  all
Liabilities relating to employees of Pfizer or any of its Affiliates; 

        (iii)  all
Liabilities under any contracts, agreements, licenses or commitments that are assigned to SuperGen at or after the Closing arising from events or activities prior
to the Closing; and 

        (iv)  all
Liabilities relating to the Excluded Assets. 

        2.2    Termination of Supply Agreement.    

        (a)   Termination.    Effective as of the Closing Date, SuperGen and Pfizer, on behalf of the Asset Selling
Corporations, agree that the Supply Agreement shall terminate and be of no further effect, other than the specific provisions set forth in Section 2.2(b). Such termination of the Supply
Agreement shall be deemed to be termination mutually agreed upon by and between SuperGen and Pfizer, on behalf of the Asset Selling Corporations, and neither Party shall have any responsibility or
liability as a result of such termination. The Parties hereby waive all rights to notice of termination as may be otherwise provided under the Supply Agreement or applicable laws. 

        (b)   Survival.    The following provisions of the Supply Agreement shall survive termination of the Supply Agreement
pursuant to Section 2.2(a) of this Agreement: (i) Section 5.1 (Notification of Complaints), Section 5.2 (Notification of Threatened Action), and Section 6.11
(Limitation of Liability), and (ii) with respect only to Product supplied before the Closing Date, Section 2.4 (Payment), Section 2.5 (Title and Risk of Loss), Section 2.6
(Conflicting Terms), Section 2.11 (Warranties) and Section 2.13 (Indemnification). 

        2.3    Amendment of Purchase Agreement.    Effective as of the Closing Date, SuperGen and Pfizer, on behalf of the
Asset Selling Corporations, agree that Section 6.17 (SuperGen's Covenant Not to Compete) of the Purchase Agreement shall be terminated and be of no further force or effect. 

        2.4    Assignment of Distribution Agreement.    Pfizer will cause WLC to assign, effective as of the Closing Date, all
of its rights and delegates all of its duties and obligations under the Distribution Agreement to SuperGen or its designated Affiliate(s). Accordingly, effective as of the Closing Date, SuperGen will
assume all of WLC's rights, duties and obligations under the Distribution Agreement. 

        2.5    Purchase Price.    

        (a)   Payment.    SuperGen or its designated Affiliate(s) shall pay Pfizer, as agent for the Asset Selling
Corporations, One Million Dollars ($1,000,000.00) (the "Purchase Price") on the Closing Date. 

        (b)   Allocation.    Pfizer, on behalf of the Asset Selling Corporations, and SuperGen hereby agree on the allocation
of the Purchase Price among the Assets and the Asset Selling Corporations, all as set forth in Schedule 2.5(b) (the
"Allocation"). Pfizer, on the one hand, and 

4

 

SuperGen,
on the other, shall (i) be bound by the Allocation for purposes of determining any Taxes, (ii) prepare and file, and cause its Affiliates to prepare and file, its Tax Returns,
including, without limitation, Internal Revenue Service Form 8594, on a basis consistent with the Allocation, and (iii) take no position, and cause its Affiliates to take no position,
inconsistent with the Allocation on any applicable Tax Return or in any proceeding before any taxing authority or otherwise. 

        2.6    Delivery Obligations; Transactions.    

        (a)   Delivery.    Pfizer shall deliver or cause to be delivered to SuperGen or its designated Affiliate(s) all
tangible Assets, provided that SuperGen shall reimburse Pfizer for any reasonable out-of-pocket expenses incurred by Pfizer or its Affiliates in the course of delivery under
this Section 2.6. After the Closing Date, Pfizer shall cooperate with SuperGen and provide all reasonable assistance to identify any and all Books and Records that are to be delivered to
SuperGen or its designated Affiliate(s) hereunder. 

        (b)   Transactions.    Within thirty (30) days after the Closing Date, Pfizer shall prepare, execute and
deliver to SuperGen or its designated Affiliate(s) all necessary notifications of change to the relevant Regulatory Authorities with respect to the change in ownership of the Marketing Approvals. 

        2.7    Closing.    The Closing shall take place at the offices of Pfizer Inc., 235 East 42nd Street, New York,
New York, United States of America at 10:00 A.M., New York time, on the second Business Day following the satisfaction or waiver of the conditions precedent specified in Article 7, or at
such other time and place as the Parties hereto may mutually agree; provided, however, that without the
agreement of Pfizer and SuperGen the Closing shall not occur later than the Closing Deadline. The date on which the Closing occurs is called the "Closing
Date". The Closing shall be deemed to occur and be effective as of the close of business on the Closing Date. 

        (a)   At
the Closing, Pfizer shall deliver, or cause to be delivered, to SuperGen the following instruments and documents, in each case in a form reasonably acceptable to
SuperGen: 

          (i)  a
general trademark assignment of all Trademarks (with trademark assignments in recordable form to be delivered after the Closing in accordance with
Section 2.8); 

         (ii)  bills
of sale, in each case dated as of the Closing Date, pursuant to which Pfizer shall transfer to SuperGen, or agree to cause the Asset Selling Corporations to
transfer to SuperGen, all of the Asset Selling Corporations' and Pfizer's right, title and interest in and to the Assets; and 

        (iii)  a
duly executed assignment appropriate to evidence WLC's assignment of its rights and obligations under the Distribution Agreement. 

        (b)   At
the Closing, SuperGen shall deliver, or cause to be delivered, to Pfizer the following: 

          (i)  the
Purchase Price, by wire transfer in immediately available funds to one or more accounts, which accounts shall be specified in writing by Pfizer at least two
Business Days prior to the Closing Date; and 

         (ii)  a
duly executed assumption agreement, in a form reasonably acceptable to Pfizer, appropriate to evidence SuperGen's assumption of WLC's rights and obligations under the
Distribution Agreement. 

        2.8    Trademarks.    SuperGen, at its sole expense, shall prepare and deliver to Pfizer or its designated
Affiliate(s) any assignments or other documents necessary to record the change in ownership of the Trademarks in each country in which there are Trademarks. SuperGen shall be solely 

5

 

responsible
for the filing and recording of all individual country Trademark assignments, and for the official fees and agent fees associated therewith. 

        2.9    Patents.    Pfizer is not aware of any Patents owned by Pfizer or any entity that is an Affiliate of Pfizer as
of the Closing Date, the claims of which Patent would be infringed upon by the making, using, selling, offering for sale or importation by SuperGen of the Product in or into a country outside of the
Prior Territory. If, after the Closing Date, Pfizer becomes aware of any such Patent, then Pfizer shall effect an assignment of such Patent to SuperGen or its designated Affiliate. 

ARTICLE 3

NON-COMPETE COVENANT  

        3.1    Covenant Not to Compete.    

        (a)   Pfizer
(itself and on behalf of its Affiliates) agrees and hereby covenants that it will not, for a period of [*] from the Closing Date, directly
or indirectly, for itself or on behalf of or in conjunction with any other entity, sell the Product pursuant to any equivalent to any foreign Abbreviated New Drug Application (a
"Generic") anywhere outside of the Prior Territory or enter into any partnership, joint venture or similar collaborative arrangement with any entity to
sell Products anywhere outside of the Prior Territory. Notwithstanding the foregoing, neither Pfizer nor any of its Affiliates shall be deemed to have violated the restriction set forth in the first
sentence of this Section 3.1 in the event that Pfizer or an Affiliate of Pfizer acquires (by purchase of stock or assets, merger or otherwise) a Generic,  provided that Pfizer or such Affiliate
thereafter divests such Generic within one year from the date of acquisition of such Generic.
 

        (b)   It
is expressly understood and agreed that if the covenant set forth in this Section 3.1 is for any reason found to be unreasonably broad, oppressive or
unenforceable in an action, suit or proceeding before any court, such court (i) shall narrow the covenant or shall otherwise endeavor to reform the scope of such covenant in order to ensure
that the application thereof is not unreasonably broad, oppressive or unenforceable, and (ii) to the fullest extent permitted by law, shall enforce such covenant as so reformed. 

        (c)   Pfizer
and SuperGen hereby agree that the breach of the covenant set forth in this Section 3.1 may cause irreparable damage to SuperGen for which monetary damages
may not be a sufficient remedy. Therefore, in addition to all other remedies that may be available to SuperGen or its Affiliate(s) at law or in equity, SuperGen and its Affiliate(s) shall be entitled
to seek specific performance and any injunctive or other equitable relief as a remedy for any breach or threatened breach of the aforementioned covenant. 

6

   ARTICLE 4

REPRESENTATIONS AND WARRANTIES  

        4.1    Representations and Warranties of Pfizer.    Pfizer hereby represents and warrants to SuperGen and its
Affiliate(s) as of the Closing Date as follows: 

        (a)   The
Asset Selling Corporations are indirect, wholly-owned subsidiaries of Pfizer, and Pfizer has all requisite power and authority to enter into this Agreement and to
consummate the transactions contemplated hereby, including without limitation to cause the Asset Selling Corporations to fulfill the obligations set forth in Article 2. The execution, delivery
and performance of this Agreement and any transactions contemplated hereunder have been duly authorized by all necessary corporate action by Pfizer and no further authorizations or actions are
required. This Agreement will, after being duly executed and delivered by Pfizer, constitute the valid and binding obligation of Pfizer, enforceable in accordance with its terms. 

        (b)   The
execution, delivery and performance of this Agreement and any transactions contemplated hereunder will not conflict with, or result in any violation of or default
under, or give rise to a right of termination, cancellation, modification or acceleration of any obligation or loss of any benefit under (any such event, a
"Conflict") (i) any provision of the charter documents or bylaws of Pfizer, (ii) any contract to which Pfizer is a party or by which its
assets are or have been bound, including the Distribution Agreement; and (iii) any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Pfizer or any of the
Assets. 

        (c)   Pfizer
is conducting its business and operations as it relates to the Assets and Distribution Agreement in compliance in all material respects with all governmental
laws, rules and regulations applicable thereto and to the best of Pfizer's Knowledge is not in violation or default in any material respect under any statute, regulation, order, decree or governmental
authorization applicable to it or any of its properties or business as presently conducted or proposed to be conducted as it relates to the Assets or the Distribution Agreement. Pfizer is not subject
to any order or consent decree of any court or administrative body that relates specifically to the Assets. 

        (d)   Pfizer
and the Asset Selling Corporations have full right, title and interest to, and as of the Closing Date will sell, convey, transfer, assign and deliver to SuperGen
or its designated Affiliate(s) good title
to all Assets. The Assets and the Distribution Agreement are free and clear of any material claim, liability, security interest or encumbrance of any party, and, except with respect to renewals of
each of the Marketing Approvals as set forth in Schedule 1.13, for which Pfizer has agreed to provide assistance to SuperGen, and renewals of
each the Trademarks as set forth in Schedule 1.24, there are no actions that must be taken within ninety (90) days after the Closing Date
(including the payment of any fees or the filing of any report) for the purposes of obtaining, maintaining, perfecting, or preserving any Marketing Approval.  Schedule 1.13 represents a full and
complete list of all Marketing Approvals for the Product for countries outside of the Prior Territory, and  Schedule 1.24 represents a full and complete list of all Trademarks for countries outside
of the Prior Territory. There are no material problems
or defects in any of the Marketing Approvals in countries set forth in Schedule 1.13 that would adversely affect such Marketing Approvals or
SuperGen's ability to manufacture, market and sell Products after the Closing Date or, as a direct result of such defects, would render the Products unmarketable for the purposes for which they were
intended. To Pfizer's Knowledge, there is no infringement by any third party of its title to the Assets. 

        (e)   There
are no adverse third party actions or claims pending against Pfizer in any court or by or before any Governmental Authority with respect to the Assets or the
Distribution Agreement. There are no other actions, suits, proceedings, claims or investigations pending against Pfizer, nor has Pfizer received notice of any of the foregoing, with respect to the
transactions 

7

 

contemplated
and hereby which, if adversely determined, would prevent Pfizer from consummating the transactions contemplated hereby. 

        (f)    Pfizer
has provided to SuperGen a true, correct and complete copy of the Distribution Agreement, and the Distribution Agreement is valid, legally binding, enforceable,
and in full force and effect, and will continue to be in full force and effect following assignment thereof to SuperGen or its designated Affiliate(s) hereunder. To the Knowledge of Pfizer:
(i) Pfizer is not in breach or default under the Distribution Agreement, (ii) Wyeth is not in breach or default thereof, and (iii) there is no dispute or threatened dispute
regarding the scope of the Distribution Agreement or performance under such agreement. 

        (g)   Except
for the Distribution Agreement, there are no outstanding material contracts, leases, instruments, obligations, commitments, understandings and agreements, whether
written or oral, to which Pfizer is a party and to which the Assets will be subject after the Closing Date. Pfizer has no material agreement with any third party that will obligate SuperGen or its
Affiliate(s) to make any payments to such third parties with respect to any of the Assets. 

        (h)   None
of the representations or warranties made by Pfizer in this Agreement contains any untrue statement of a material fact or omits to state any material fact necessary
in order to make the statements contained herein or therein, in light of the circumstances under which made, not misleading. 

        4.2    Representations and Warranties of SuperGen.    SuperGen hereby represents and warrants to Pfizer as of the
Closing Date as follows: 

        (a)   SuperGen
has all requisite power and authority to enter into this Agreement and consummate the transactions contemplated hereunder. The execution, delivery and
performance of this Agreement and the transactions contemplated herein have been duly authorized by all necessary corporate action by SuperGen and no further authorizations or actions are required.
This Agreement has been duly executed and delivered by SuperGen and constitutes the valid and binding obligation of SuperGen, enforceable in accordance with its terms. 

        (b)   The
execution, delivery and performance of this Agreement and the transactions contemplated hereunder will not result in any Conflict with (i) any provision of
the charter documents or bylaws of SuperGen, or (ii) any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to SuperGen or any of its assets. 

        (c)   None
of the representations or warranties made by SuperGen in this Agreement contains any untrue statement of a material fact or omits at the Closing Date to state any
material fact necessary in order to make the statements contained herein or therein, in light of the circumstances under which made, not misleading. 

        4.3    No Reliance.    In light of the representations and warranties made by the Parties in this Article 4,
each Party is relinquishing any right to any claim based on any representations and warranties, other than those specifically included in Section 4.1. Any claims a Party may have for breach of
representation or warranty shall be based solely on the representations and warranties made in this Article 4. All warranties of habitability, merchantability and fitness for any particular
purpose, and all other warranties arising under the Uniform Commercial Code (or similar foreign laws), are hereby waived by each Party. 

ARTICLE 5

COVENANTS  

        5.1    Access to Information.    After the Closing, Pfizer shall afford SuperGen and its accountants, counsel and
other representatives, reasonable access during normal business hours as may be 

8

 

appropriate,
to the Books and Records and all other information concerning the Assets as SuperGen may reasonably request. No information or knowledge obtained in any investigation pursuant to this
Section 5.1 shall affect or be deemed to modify any representation or warranty contained herein. 

        5.2    Further Assurances.    Without further consideration, each Party shall, and shall cause its employees and
Affiliates to, execute and deliver such other instruments or documents as may be reasonably requested by the other Party (provided that the requesting Party shall reimburse the other Party for any
reasonable out-of-pocket expenses incurred in the course of such delivery) in order to more effectively consummate the transactions prepared and contemplated by this Agreement
and to confirm SuperGen's interest in and to the Assets. 

        5.3    Additional Deliveries.    Pfizer agrees to use commercially reasonable efforts to locate, and, if located, to
deliver or cause its Affiliates to deliver to SuperGen the Subsequent Acquired Know-How, if any, and the Subsequent Licensed Know-How, if any, as reasonably requested by
SuperGen, including, but not limited to the Drug Master Files, batch records relating to the fermentation process for the Product, marketing materials related to the Product, and biological materials
used in the manufacture of the Product; provided in each case, however, that (i) such know-how is reasonably available to Pfizer, and (ii) SuperGen shall reimburse Pfizer for
any reasonable out-of-pocket expenses incurred by Pfizer or its Affiliates in the course of delivery under this Section 5.3. 

        5.4    Regulatory Authority Reporting.    

        (a)   After
the Closing Date, and for so long as Pfizer remains the registered owner of any Marketing Approval for the Product in a country outside of the Prior Territory
where the Product is presently marketed by Wyeth, Pfizer will continue to receive, process, assess and maintain the database for reports of adverse events for the Product in such country. During this
time, Pfizer will provide SuperGen with a copy of each Council for International Organizations of Medical Sciences (CIOMS) report for the Product that Pfizer sends to Pfizer's local Affiliate(s) with
respect to the Product at the same time that Pfizer sends the CIOMS report to Pfizer's local Affiliate(s). 

        (b)   After
the Closing Date SuperGen shall be responsible for making all required reports for the Product to Regulatory Authorities in countries for which the Market Approval
for the Product has been transferred to SuperGen pursuant to this Agreement, including but not limited to, the filing of annual reports and the filing and/or monitoring of adverse events or complaints
reported to Pfizer or any of its Affiliates. For avoidance of doubt, SuperGen shall be responsible, to the extent required by applicable law, for making all required reports for the Product to the
EMEA. 

        (c)   After
the Marketing Approval for the United Kingdom (the Reference Member State for the Product), transfers from Pfizer to SuperGen, SuperGen shall submit all CIOMS
reports to the Regulatory Authorities in the United Kingdom including those for the Prior Territory and those provided by Pfizer under Section 5.3(a). 

        (d)   Pfizer
and SuperGen will adhere to the process described in Sections 5.3(a)-(c) until the date on which record ownership of the last Marketing Approval has been
transferred to SuperGen (the "Last Transfer Date"). Following the Last Transfer Date, Pfizer will have no further obligations to, and will no longer, assess, database or report to any Regulatory
Authorities adverse event cases for the Product received by Pfizer, but will, for the twelve (12) month period starting with the Last Transfer Date, promptly provide SuperGen with such
information as SuperGen or its Affiliates shall reasonably require in order to comply with all applicable laws. 

        (e)   Promptly
after the Closing Date, the Parties will discuss and agree upon a plan for transfer, after the Last Transfer Date, of the safety database for the Product
maintained by Pfizer to SuperGen. 

9

 

        5.5    Transition.    To effect a smooth transition from Pfizer to the SuperGen with respect to the Product and Assets
pursuant to this Agreement, for a period of 180 days commencing on the Closing Date, Pfizer will (a) if not completed prior to the Closing, seek to complete the renewal process for the
Marketing Approvals for the Product which process was commenced by Pfizer prior to the Closing; (b) provide reasonable assistance to SuperGen, as requested by SuperGen, in connection with the
transfer of the Marketing Approvals for the Product to SuperGen; and (c) provide to SuperGen such information in the possession of Pfizer as may reasonably be required by SuperGen to ensure an
orderly transition of the Product and the Assets to SuperGen. 

        5.6    Labeling.    For up to 180 days after the Closing Date, SuperGen may continue to use Pfizer's (or its
Affiliate's) Labeling on the Product. After such time, the Product shall be manufactured with Labeling and packaging identifying SuperGen (or SuperGen's designee) as the owner of the Marketing
Approval. SuperGen shall amend the Labeling in each country as soon as practicable from the date SuperGen completes the registration ownership transfer process in such country, but in no event later
than 90 days thereafter. With respect to Product sold after the Closing Date, as between Pfizer and SuperGen, SuperGen shall be solely responsible for ensuring that the Labeling and other
printed materials, if any, comply with all applicable laws and regulations. 

ARTICLE 6

SURVIVAL OF REPRESENTATIONS,

WARRANTIES AND INDEMNIFICATION  

        6.1    Survival of Representations and Warranties.    All of the representations and warranties contained herein shall
survive the Closing Date and continue in full force and effect for a period of one (1) year thereafter. 

        6.2    Indemnification of SuperGen.    Pfizer agrees to indemnify, defend and hold harmless SuperGen and its officers,
directors and Affiliates (the "SuperGen Indemnified Parties") from and against all claims, losses, liabilities, damages, deficiencies, costs and
expenses, including reasonable attorneys' fees and expenses, and expenses of investigation and defense (hereinafter collectively "Losses"), incurred or
suffered by the SuperGen Indemnified Parties directly or indirectly as a result of (i) any breach of a representation or warranty of Pfizer contained in this Agreement; (ii) any failure
by Pfizer to comply with any covenant contained in this Agreement; or (iii) any Retained Liabilities. 

        6.3    Indemnification of Pfizer.    SuperGen agrees to indemnify, defend and hold harmless Pfizer and its officers,
directors and Affiliates (the "Pfizer Indemnified Parties") from and against all Losses incurred or suffered by the Pfizer Indemnified Parties directly
or indirectly as a result of (i) any or breach of a representation or warranty of SuperGen contained in this Agreement; (ii) any failure by SuperGen to comply with any covenant contained
in this Agreement; (iii) any activities relating to the Distribution Agreement that occur after the Closing Date; or (iv) any other events or activities that occur after the Closing Date
with respect to the Product. 

        6.4    Procedure.    

        (a)   Claim Notice.    Any party that may be entitled to indemnification under this Article 6 (an
"Indemnified Party") shall send to the Party obligated to indemnify it (the "Indemnifying Party") prompt
written notice of any claim, demand, action or other proceeding made against the Indemnified Party or which the Indemnified Party has reasonable grounds to believe may be made against the Indemnified
Party (a "Claim Notice"). Any Claim Notice shall specify in reasonable detail the basis of such claim or anticipated claim, and the nature of the breach
of representation, warranty or covenant to which such item is related. The failure to deliver a Claim Notice reasonably promptly upon receipt of notice by the Indemnified Party of any such Loss
anticipated Loss shall not relieve the Indemnifying Party of any indemnification obligations hereunder, unless such failure materially and adversely prejudiced the Indemnifying Party. 

10

 

        (b)   Objection.    In case the Indemnifying Party shall object in writing to any claim or claims made in any Claim
Notice within thirty (30) days after delivery of such Claim Notice, the Indemnifying Party and the Indemnified Party shall attempt in good faith for sixty (60) days to resolve such
dispute. If the Parties should so agree, a memorandum setting forth such agreement shall be prepared and signed by all such Parties. 

        (c)   Defense; Settlement. 

          (i)  The
Indemnifying Party shall have the right to assume and control the defense and/or, at its option, settlement of any claim that is subject indemnification hereunder,
with counsel selected by the Indemnifying Party. The Indemnified Party, its employees and agents, shall at the Indemnifying Party's expense, reasonably cooperate with the Indemnifying Party and its
legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Article 6. 

         (ii)  The
indemnity obligations under this Article 6 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement
is effected without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably conditioned, withheld or delayed. The Indemnifying Party may not settle or otherwise
consent to an adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights or interests of, or adversely affects, the Indemnified Party without the prior express
written consent of the Indemnified Party, which consent shall not be unreasonably conditioned, withheld or delayed. 

        6.5    Certain Limitations.    Pfizer shall not have any indemnification obligation under Section 6.2 for
Losses unless the aggregate of all such Losses for which Pfizer would, but for this provision, be liable exceeds on a cumulative basis [*], but if such amount is exceeded,
Pfizer shall be required to pay only the amount of such Losses which in the aggregate exceed [*]; provided however, that Pfizer
shall have no indemnification obligation under Section 6.2 for Losses (x) for any individual item where the Loss relating thereto is less than [*] and
(y) which in the aggregate are in excess of [*]. 

        6.6    Sole Remedy/Waiver.    The Parties hereto acknowledge and agree that the remedies provided for in this
Agreement shall be the Parties' sole and exclusive remedy with respect to the subject matter of this Agreement, except for claims for injunctive relief resulting from a breach or threatened breach of
Article 8 hereof. In furtherance of the foregoing, each Party hereby waives, to the fullest extent permitted by applicable law, any and all other rights, claims and causes of action (including
rights of contribution, if any) known or unknown, foreseen or unforeseen, which exist or may arise in the future, that it may have against Pfizer or any of its Affiliates, or SuperGen or any of its
Affiliates, as the case may be, arising under or based upon any federal, state or local law. 

        6.7    No Consequential Damages.    NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, NO PARTY TO THIS
AGREEMENT SHALL BE LIABLE TO OR OTHERWISE RESPONSIBLE TO ANY OTHER PARTY HERETO OR ANY AFFILIATE OF ANY OTHER PARTY HERETO FOR SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES OR FOR DIMINUTION
IN VALUE OR LOST PROFITS THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR ANY LIABILITY RETAINED OR ASSUMED HEREUNDER. 

ARTICLE 7

CLOSING CONDITIONS; WAIVER  

        7.1    Closing Conditions.    The respective obligations of each Party under this Agreement are subject to the
satisfaction on the Closing Date of the following conditions, provided that compliance 

11

 

with
any such conditions or parts thereof may be waived by the applicable Party in accordance with Section 7.2: 

        (a)   The
representations and warranties of each Party set forth in Article 4 (other than those set forth in Section 4.1(c)) shall be true in all material
respects and each Party shall have performed all obligations and conditions herein required to be performed except with respect to representatives and warranties that expressly relate to a particular
date, which must be true in all material respects as of such date or observed by it on or prior to the Closing Date. 

        (b)   No
Governmental Authority shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, executive order, decree, injunction or other order
(whether temporary, preliminary or permanent) which is in effect and which has the effect of making the transactions contemplated hereby illegal or otherwise prohibiting consummation of the
transactions contemplated hereunder, nor shall any proceeding brought by a Governmental Authority seeking any of the foregoing be pending. 

        7.2    Extension; Waiver.    At any time, Pfizer and SuperGen may (i) extend the time for the performance of
any of the obligations of the other Party hereto, (ii) waive any inaccuracies in the representations and warranties made to such Party contained herein or in any document delivered pursuant
hereto, and (iii) waive compliance with any of the agreements or conditions for the benefit of such Party contained herein. Any agreement on the part of a Party hereto to any such extension or
waiver shall be valid only if set forth in an instrument in writing signed on behalf of such Party. 

ARTICLE 8

CONFIDENTIAL INFORMATION  

        8.1    Confidential Information.    Each Party agrees, and shall cause its Affiliates, employees and agents to agree,
to maintain in confidence all confidential or proprietary information disclosed to it by the other Party for the five (5) year period from the Closing Date, and shall not use, disclose or grant
the use of the confidential information provided by the other Party during such five (5) year period except (i) to the extent such use or disclosure is reasonably necessary in connection
with such Party's performance of its obligations and exercise of its rights and licenses under this Agreement, provided that any such authorized disclosure is made pursuant to a binding obligation of
confidentiality no less protective of such confidential information than this Section 8.1 or (ii) in prosecuting or defending litigation, complying with applicable governmental laws,
regulations or court order or otherwise submitting information to tax or other governmental authorities; provided that if a Party is required by law to make any such disclosure, other than pursuant to
a confidentiality agreement, it will give reasonable advance notice to the other Party of such disclosure and, save to the extent inappropriate in the case of patent applications or the like, will use
its reasonable efforts to secure confidential treatment of such information in consultation with the other Party prior to its disclosure (whether through protective orders or otherwise) and disclose
only the minimum necessary to comply with such requirements. Each Party shall use the same level of care to protect against unauthorized use and disclosure of the other Party's confidential
information that such Party uses in protecting its own confidential information, but in no event less than reasonable care. Each Party shall notify the other promptly upon discovery of any
unauthorized use or disclosure of the other Party's confidential information. For clarity the Assigned Technology shall be deemed the confidential information of SuperGen. This Article 8 shall
apply to confidential information disclosed pursuant to the Purchase Agreement and the Supply Agreement. 

        8.2    Exclusions.    The confidentiality obligations contained in Section 8.1 shall not apply to the extent
that the disclosed information: (i) was in the public domain at the time it was disclosed or has entered the public domain through no fault of the receiving Party (the
"Recipient"); (ii) was known to the Recipient, without restriction, at the time of disclosure, as demonstrated by the Recipient's files in 

12

 

existence
at the time of disclosure; (iii) was independently developed by the Recipient without any use of the confidential information of the disclosing Party, as demonstrated by files created
at the time of such independent development; (iv) is obtained from a third party, without restriction, who had the legal right to disclose the same to the Recipient. 

ARTICLE 9

GENERAL  

        9.1    No Agency.    Each Party shall in all matters relating to this Agreement act as an independent contractor.
Neither Party shall have authority, nor shall either Party represent that it has any authority, to assume or create any obligation, express or implied, on behalf of the other, or to represent the
other Party as agent or employee or in any other capacity. Neither execution nor performance of this Agreement shall be construed to have established any agency, joint venture, or partnership. 

        9.2    Notices.    Any notice or other communication required or permitted to be delivered to any Party under this
Agreement must be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by confirmed facsimile)
to the address or facsimile telephone number set forth beneath the name of such Party below (or to such other address or facsimile telephone number as such Party may have specified in a written notice
given to the other Party): 

	if to SuperGen:	 	SuperGen, Inc.

4140 Dublin Boulevard, Suite 200

Dublin, California 94568

Attn: [*]

Telephone: [*]

Facsimile: [*]
	

with a copy to:	
 	

[*]

Wilson Sonsini Goodrich & Rosati

650 Page Mill Road

Palo Alto, CA 94304

Telephone: [*]

Facsimile: [*]
	

if to Pfizer:	
 	

Pfizer Inc.

235 East 42nd Street

New York, New York 10017

Attn: [*]

Telephone: [*]

Facsimile: [*]
	

with a copy to:	
 	

Pfizer Inc.

235 East 42nd Street

New York, New York 10017

Attn: [*]

Telephone: [*]

Facsimile: [*]

        9.3    Governing Law.    This Agreement shall be governed in all respects by the laws of the United States of America
and the State of Delaware. 

        9.4    Breaches and Remedies.    Except as otherwise provided herein, any and all remedies herein expressly conferred
upon a Party will be deemed cumulative with and not exclusive of any other remedy 

13

 

conferred
hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. 

        9.5    Waiver.    No failure on the part of a Party to exercise any power, right, privilege, or remedy under this
Agreement, and no delay on the part of any Party in exercising any power, right, privilege, or remedy under this Agreement, will operate as a waiver of such power, right, privilege, or remedy; and no
single or partial exercise of any such power, right, privilege, or remedy will preclude any other or further exercise thereof or of any other power, right, privilege, or remedy. Except as otherwise
expressly provided herein, no Party shall be deemed to have waived any claim arising from this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such
claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party; and any such waiver will not be applicable or have any
effect except in the specific instance in which it is given. 

        9.6    Assignment.    No Party to this Agreement may assign any of its rights or obligations under this Agreement
without the prior written consent of the other Party hereto, except that SuperGen may without such consent assign its rights and obligations hereunder to one or more of its Affiliates or to any
successor to all or substantially all of its pharmaceuticals business. No such assignment will relieve the assigning Party of any of its liabilities hereunder. For the avoidance of doubt, nothing in
this Section 9.6 shall prevent SuperGen from transferring the Assets or sublicensing any license rights granted hereunder or under the Purchase Agreement (to the extent SuperGen otherwise has
the right to do so), provided that Pfizer's obligations to SuperGen hereunder (including without limitation those
in Articles 5 and 6) shall not be assigned to the transferee, other than as permitted in the first sentence of this Section 9.6. 

        9.7    Amendment.    The Parties may amend this Agreement at any time by execution of an instrument in writing signed
on behalf of each of the Parties hereto. 

        9.8    Severability.    If, for any reason, a court of competent jurisdiction finds any provision of this Agreement,
or portion thereof, to be invalid or unenforceable, such provision of the Agreement will be enforced to the maximum extent permissible so as to affect the intent of the Parties, and the remainder of
this Agreement will continue in full force and effect. The Parties agree to negotiate in good faith an enforceable substitute provision for any unenforceable provision that most nearly achieves the
intent and economic effect of the unenforceable provision. 

        9.9    Entire Agreement.    This Agreement (including the Schedules attached hereto) along with the Purchase
Agreement, as amended hereby, sets forth the entire understanding of the Parties hereto relating to the subject matter hereof and except as expressly provided in Section 2.2(b) supersedes all
prior agreements and understandings between the Parties hereto relating to the subject matter hereof. 

        9.10    Counterparts.    This Agreement may be executed in counterparts, which, when taken together, shall constitute
one agreement. 

        9.11    Public Disclosure.    Notwithstanding anything herein to the contrary, each of the Parties to this Agreement
hereby agrees with the other Party hereto that, except as may be required to comply with the requirements of any applicable laws, and the rules and regulations of each stock exchange upon which the
securities of either of the Parties is listed, no press release or similar public announcement or communication shall be made or caused to be made concerning the execution or performance of this
Agreement unless the Parties shall have mutually agreed in advance with respect thereto. 

[Remainder of page intentionally left blank] 

14

        IN WITNESS WHEREOF, the Parties, by their duly authorized representatives, have executed this Agreement as of the date first written above. 

	PFIZER INC.	 	SUPERGEN, INC.
	

By:	
 	

 	
 	

By:	
 	

 
	 	 	
	 	 	 	

	

Name:	
 	

 	
 	

Name:	
 	

 
	 	 	
	 	 	 	

	

Title:	
 	

 	
 	

Title:	
 	

 
	 	 	
	 	 	 	

[Remainder of page intentionally left blank] 

Schedule 1.3

Asset Selling Corporations  

Warner-Lambert
Company LLC 

Warner-Lambert
N.V 

Pfizer
ApS 

Goedecke
GmbH 

Pfizer
Hellas AE 

Warner-Lambert Ltd.

Pfizer
Italia S.r.l 

Warner-Lambert
N.V 

Pfizer
BV 

Laboratorios,
Pfizer Lda. 

Warner-Lambert Ltd. 

Parke
Davis, S.L. 

Pfizer
SAS 

Schedule 1.10

Knowledge of Pfizer  

	Name
 
	 	Title
 

	[*]	 	[*]

   Schedule 1.13

Marketing Approvals  

	Country
 
	 	Type of

application
	 	Marketing Status
	 	Registration date
	 	Required Renewal

Date

	[*]	 	[*]	 	[*]	 	[*]	 	[*]

2

   Schedule 1.24

Trademarks  

	Trademark
 
	 	Country
	 	Status
	 	Appln No.
	 	Appln Dt.
	 	Reg. No.
	 	Reg. Dt.
	 	Action Due
	 	Action Due

Date

	NEPENT	 	Portugal	 	Registered	 	288000	 	15DE1992	 	288000	 	09SE1994	 	RENEWAL	 	09SE2004
	NEPENT	 	Switzerland	 	Registered	 	721/1993/9	 	28JA1993	 	404937	 	28JA1993	 	RENEWAL	 	28JA2013
	NIPENT	 	Argentina	 	Registered	 	1863817	 	27NO1992	 	1533131	 	29JL1994	 	RENEWAL	 	29JL2004
	NIPENT	 	Australia	 	Registered	 	572044	 	06FE1992	 	A572044	 	20AU1993	 	RENEWAL	 	06FE2009
	NIPENT	 	Austria	 	Registered	 	AM1225/92	 	13MR1992	 	142593	 	26JE1992	 	RENEWAL	 	30JE2012
	NIPENT	 	Benelux	 	Registered	 	73199	 	07FE1992	 	510378	 	07FE1992	 	RENEWAL	 	07FE2012
	NIPENT	 	Bosnia-Herzegovina	 	Registered	 	BAZ96724A	 	27MY1996	 	BAZ96724	 	22MY2001	 	RENEWAL	 	27MY2006
	NIPENT	 	Brazil	 	Registered	 	817009191	 	07DE1992	 	817009191	 	07JE1994	 	RENEWAL	 	07JE2004
	NIPENT	 	Chile	 	Registered	 	200789	 	21SE1992	 	392835	 	23JE1993	 	RENEWAL	 	28NO2012
	NIPENT	 	Costa Rica	 	Registered	 	NONE	 	18JA1993	 	83154	 	12JL1993	 	RENEWAL	 	12JL2013
	NIPENT	 	Czech Republic	 	Registered	 	71546-92	 	04SE1992	 	179291	 	31AU1994	 	RENEWAL	 	04SE2012
	NIPENT	 	Ecuador	 	Registered	 	35894/92	 	10DE1992	 	73/94	 	01FE1994	 	RENEWAL	 	01FE2004
	NIPENT	 	Estonia	 	Registered	 	9303725	 	14AP1993	 	16108	 	30JE1995	 	RENEWAL	 	30JE2005
	NIPENT	 	France	 	Registered	 	292642	 	19JE1991	 	1672107	 	19JE1991	 	RENEWAL	 	18JE2011
	NIPENT	 	Great Britain	 	Registered	 	1467255	 	12JE1991	 	1467255	 	23OC1992	 	RENEWAL	 	12JE2008
	NIPENT	 	Georgia	 	Registered	 	T1998013148	 	24FE1998	 	11269	 	11DE1998	 	RENEWAL	 	11DE2008
	NIPENT	 	Germany	 	Registered	 	W41873/5WZ	 	27JE1991	 	2044619	 	10SE1993	 	RENEWAL	 	30JE2011
	NIPENT	 	Greece	 	Registered	 	107634	 	06FE1992	 	107634	 	17OC1994	 	RENEWAL	 	06FE2012
	NIPENT	 	Guatemala	 	Registered	 	279-93	 	18JA1993	 	75495	 	31AU1995	 	RENEWAL	 	30AU2005
	NIPENT	 	Honduras	 	Registered	 	10700/93	 	26OC1993	 	60117	 	18JL1994	 	NON USE TAX	 	28FE2004
	NIPENT	 	Hong Kong	 	Registered	 	1232/92	 	21FE1992	 	102/1994	 	10JA1994	 	RENEWAL	 	21FE2013
	NIPENT	 	Ireland	 	Registered	 	92/0692	 	06FE1992	 	149923	 	09JE1994	 	RENEWAL	 	05FE2009
	NIPENT	 	Italy	 	Registered	 	91C002241	 	19JE1991	 	612995	 	29DE1993	 	RENEWAL	 	19JE2011
	NIPENT	 	Jamaica	 	Registered	 	5/4846	 	04DE1992	 	26733	 	04JL1996	 	RENEWAL	 	04DE2013
	NIPENT	 	Japan	 	Registered	 	8159/1992	 	30JA1992	 	2685981	 	29JL1994	 	RENEWAL	 	29JL2004
	NIPENT	 	South Korea	 	Registered	 	92-3034	 	08FE1992	 	260438	 	07AP1993	 	RENEWAL	 	07AP2013
	NIPENT	 	Latvia	 	Registered	 	M-93-2210	 	08MR1993	 	M33895	 	20OC1996	 	RENEWAL	 	08MR2013
	NIPENT	 	Lithuania	 	Registered	 	12925	 	05OC1993	 	23930	 	16DE1996	 	RENEWAL	 	05OC2013
	NIPENT	 	New Zealand	 	Registered	 	216056	 	07FE1992	 	216056	 	09NO1994	 	RENEWAL	 	07FE2013
	NIPENT	 	Nicaragua	 	Registered	 	93-00408	 	16FE1993	 	24469	 	26NO1993	 	RENEWAL	 	25NO2013
	NIPENT	 	Norway	 	Registered	 	93/3664	 	03AU1993	 	167356	 	23MR1995	 	RENEWAL	 	23MR2005
	NIPENT	 	Panama	 	Registered	 	68800	 	10DE1993	 	68800	 	27JE1995	 	RENEWAL	 	27JE2005
	NIPENT	 	Paraguay	 	Registered	 	19195	 	26NO1992	 	163292	 	19AU1993	 	RENEWAL	 	19AU2013
	NIPENT	 	Poland	 	Registered	 	Z-113345	 	09SE1992	 	79101	 	28OC1994	 	RENEWAL	 	09SE2012
	NIPENT	 	Portugal	 	Registered	 	288001	 	15DE1992	 	288001	 	09SE1994	 	RENEWAL	 	09SE2004
	NIPENT	 	Romania	 	Registered	 	27768	 	16SE1992	 	19850	 	05JE1996	 	RENEWAL	 	16SE2012
	NIPENT	 	South Africa	 	Registered	 	92/0938	 	06FE1992	 	92/0938	 	21MR1994	 	RENEWAL	 	06FE2012
	NIPENT	 	El Salvador	 	Registered	 	4035/92	 	27NO1992	 	172	 	12DE1996	 	RENEWAL	 	12DE2006
	NIPENT	 	Serbia-Montenegro	 	Registered	 	Z-1127/92	 	16SE1992	 	40306	 	19SE1997	 	RENEWAL	 	16SE2012
	NIPENT	 	Slovak Republic	 	Registered	 	71546-92	 	04SE1992	 	174929	 	14JE1995	 	RENEWAL	 	04SE2012
	NIPENT	 	Spain	 	Registered	 	1645121	 	27JE1991	 	1645121	 	04MR1994	 	RENEWAL	 	27JE2011
	NIPENT	 	Switzerland	 	Registered	 	722/1993.0	 	28JA1993	 	404938	 	28JA1993	 	RENEWAL	 	28JA2013
	NIPENT	 	Taiwan	 	Filed	 	91046026	 	01NO2002	 	 	 	 	 	 	 	 
	NIPENT	 	Ukraine	 	Registered	 	93084118	 	03AU1993	 	8846	 	31OC1997	 	RENEWAL	 	03AU2013
	NIPENT	 	Uruguay	 	Registered	 	258929	 	30NO1992	 	258929	 	23SE1994	 	RENEWAL	 	23SE2004
	ONCOPENT	 	Australia	 	Registered	 	572045	 	06FE1992	 	A572045	 	20AU1993	 	RENEWAL	 	06FE2009
	ONCOPENT	 	Austria	 	Registered	 	AM1226/92	 	13MR1992	 	142594	 	26JE1992	 	RENEWAL	 	30JE2012
	ONCOPENT	 	Benelux	 	Registered	 	73200	 	07FE1992	 	510379	 	07FE1992	 	RENEWAL	 	07FE2012
	ONCOPENT	 	Brazil	 	Registered	 	817009205	 	07DE1992	 	817009205	 	07JE1994	 	RENEWAL	 	07JE2004
	ONCOPENT	 	Costa Rica	 	Registered	 	NONE	 	18JA1993	 	84699	 	10NO1993	 	RENEWAL	 	10NO2013
	ONCOPENT	 	Denmark	 	Registered	 	1013/1992	 	11FE1992	 	6248/1992	 	10JL1992	 	RENEWAL	 	10JL2012
	ONCOPENT	 	Ecuador	 	Registered	 	35895/92	 	10DE1992	 	74/94	 	01FE1994	 	RENEWAL	 	01FE2004
	ONCOPENT	 	Finland	 	Registered	 	1951/92	 	21AP1992	 	125826	 	05MR1993	 	RENEWAL	 	05MR2013
	ONCOPENT	 	France	 	Registered	 	290553	 	10JE1991	 	1670406	 	10JE1991	 	RENEWAL	 	09JE2011
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

1

 

	ONCOPENT	 	Greece	 	Registered	 	107633	 	06FE1992	 	107633	 	17OC1994	 	RENEWAL	 	06FE2012
	ONCOPENT	 	Guatemala	 	Registered	 	282-93	 	18JA1993	 	72589	 	30AU1994	 	RENEWAL	 	29AU2004
	ONCOPENT	 	Hong Kong	 	Registered	 	1234/92	 	21FE1992	 	103/1994	 	10JA1994	 	RENEWAL	 	21FE2013
	ONCOPENT	 	Ireland	 	Registered	 	92/0693	 	06FE1992	 	149924	 	09JE1994	 	RENEWAL	 	05FE2009
	ONCOPENT	 	Italy	 	Registered	 	RM91C002149	 	13JL1991	 	612913	 	29DE1993	 	RENEWAL	 	13JL2011
	ONCOPENT	 	Jamaica	 	Registered	 	5/4847	 	04DE1992	 	25906	 	09JA1996	 	RENEWAL	 	04DE2013
	ONCOPENT	 	Japan	 	Registered	 	8160/1992	 	30JA1992	 	2665074	 	31MY1994	 	RENEWAL	 	31MY2004
	ONCOPENT	 	South Korea	 	Registered	 	92-3035	 	08FE1992	 	260439	 	07AP1993	 	RENEWAL	 	07AP2013
	ONCOPENT	 	New Zealand	 	Registered	 	216057	 	07FE1992	 	216057	 	14DE1994	 	RENEWAL	 	07FE2013
	ONCOPENT	 	Nicaragua	 	Registered	 	93-00409	 	16FE1993	 	24468	 	26NO1993	 	RENEWAL	 	25NO2013
	ONCOPENT	 	Norway	 	Registered	 	93/3665	 	03AU1993	 	167357	 	23MR1995	 	RENEWAL	 	23MR2005
	ONCOPENT	 	Paraguay	 	Filed	 	19194	 	26NO1992	 	 	 	 	 	 	 	 
	ONCOPENT	 	Portugal	 	Registered	 	288002	 	15DE1992	 	288002	 	09SE1994	 	RENEWAL	 	09SE2004
	ONCOPENT	 	South Africa	 	Registered	 	92/0939	 	06FE1992	 	92/0939	 	21MR1994	 	RENEWAL	 	06FE2012
	ONCOPENT	 	El Salvador	 	Registered	 	4036/92	 	27NO1992	 	195	 	12MY1995	 	RENEWAL	 	12MY2005
	ONCOPENT	 	Sweden	 	Registered	 	92-1338	 	06FE1992	 	250724	 	13AU1993	 	RENEWAL	 	13AU2013
	ONCOPENT	 	Switzerland	 	Registered	 	723/1993/2	 	28JA1993	 	404939	 	28JA1993	 	RENEWAL	 	28JA2013
	ONCOPENT	 	Uruguay	 	Registered	 	258930	 	30NO1992	 	258930	 	07MY1993	 	RENEWAL	 	07MY2013
	ONCOPENT	 	Venezuela	 	Registered	 	6386/92	 	31MR1992	 	169840	 	07OC1994	 	RENEWAL	 	07OC2004

2

Schedule 2.5(b)

Allocation of the Purchase Price  

Among the Asset Selling Corporations  

[*] 

Among the Assets  

[*]

CONFIDENTIAL
TREATMENT REQUEST 

	*
	Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

QuickLinks

PURCHASE AND SALE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]